舒林酸衍生的Ras通路抑制剂作用于Ras-Raf相互作用以及Ras通路中的下游效应分子。 - Suppr

Sulindac-derived Ras pathway inhibitors target the Ras-Raf interaction and downstream effectors in the Ras pathway.

作者信息

Waldmann Herbert, Karaguni Ioanna-Maria, Carpintero Mercedes, Gourzoulidou Eleni, Herrmann Christian, Brockmann Christoph, Oschkinat Hartmut, Müller Oliver

机构信息

Max-Planck-Institut für molekulare Physiologie, Abteilung Chemische Biologie, Dortmund, Germany.

出版信息

Angew Chem Int Ed Engl. 2004 Jan 16;43(4):454-8. doi: 10.1002/anie.200353089.

DOI:10.1002/anie.200353089

PMID:14735533

Abstract

摘要

相似文献

Sulindac-derived Ras pathway inhibitors target the Ras-Raf interaction and downstream effectors in the Ras pathway.舒林酸衍生的Ras通路抑制剂作用于Ras-Raf相互作用以及Ras通路中的下游效应分子。

Angew Chem Int Ed Engl. 2004 Jan 16;43(4):454-8. doi: 10.1002/anie.200353089.

Identification of potent Ras signaling inhibitors by pathway-selective phenotype-based screening.通过基于途径选择性表型的筛选鉴定有效的Ras信号抑制剂。

Angew Chem Int Ed Engl. 2004 Jan 16;43(4):450-4. doi: 10.1002/anie.200352587.

The new sulindac derivative IND 12 reverses Ras-induced cell transformation.新型舒林酸衍生物IND 12可逆转Ras诱导的细胞转化。

Cancer Res. 2002 Mar 15;62(6):1718-23.

Protein kinase Cepsilon is oncogenic in colon epithelial cells by interaction with the ras signal transduction pathway.蛋白激酶Cε通过与ras信号转导途径相互作用在结肠上皮细胞中具有致癌性。

Oncogene. 1998 Jun 25;16(25):3345-8. doi: 10.1038/sj.onc.1201871.

Ras effector pathways modulate scatter factor-stimulated NF-kappaB signaling and protection against DNA damage.Ras效应器通路调节散射因子刺激的NF-κB信号传导及对DNA损伤的保护作用。

Oncogene. 2007 Jul 19;26(33):4774-96. doi: 10.1038/sj.onc.1210271. Epub 2007 Feb 12.

Influence of K-ras activation on the survival responses of Caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine.K-ras激活对Caco-2细胞对化学预防剂舒林酸和二氟甲基鸟氨酸存活反应的影响。

Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1155-62.

Transmembrane signaling pathway mediates oxidized low-density lipoprotein-induced expression of plasminogen activator inhibitor-1 in vascular endothelial cells.跨膜信号通路介导氧化型低密度脂蛋白诱导血管内皮细胞中纤溶酶原激活物抑制剂-1的表达。

Am J Physiol Endocrinol Metab. 2008 Nov;295(5):E1243-54. doi: 10.1152/ajpendo.90415.2008. Epub 2008 Sep 16.

Transient kinetic studies on the interaction of Ras and the Ras-binding domain of c-Raf-1 reveal rapid equilibration of the complex.关于Ras与c-Raf-1的Ras结合结构域相互作用的瞬态动力学研究揭示了该复合物的快速平衡。

Biochemistry. 1998 Oct 6;37(40):14292-9. doi: 10.1021/bi980764f.

Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.RAF/丝裂原活化蛋白/细胞外信号调节激酶激酶/细胞外信号调节激酶信号通路的激活介导了白屈菜红碱诱导骨肉瘤细胞凋亡的过程。

Clin Cancer Res. 2008 Oct 15;14(20):6396-404. doi: 10.1158/1078-0432.CCR-07-5113.

The antitumor ether lipid 1-Q-octadecyl-2-O-methyl-rac-glycerophosphocholine (ET-18-OCH3) inhibits the association between Ras and Raf-1.抗肿瘤醚脂1-Q-十八烷基-2-O-甲基-外消旋甘油磷酸胆碱（ET-18-OCH3）可抑制Ras与Raf-1之间的结合。

Anticancer Res. 2003 May-Jun;23(3B):2291-5.

引用本文的文献

The complex journey of targeting RAS in oncology.肿瘤学中靶向RAS的复杂历程。

BMC Cancer. 2025 Jul 1;25(1):1053. doi: 10.1186/s12885-025-14033-y.

The Multi-Level Mechanism of Action of a Pan-Ras Inhibitor Explains its Antiproliferative Activity on Cetuximab-Resistant Cancer Cells.一种泛Ras抑制剂的多级作用机制解释了其对西妥昔单抗耐药癌细胞的抗增殖活性。

Front Mol Biosci. 2021 Feb 17;8:625979. doi: 10.3389/fmolb.2021.625979. eCollection 2021.

Small molecule inhibitors of RAS proteins with oncogenic mutations.具有致癌突变的 RAS 蛋白的小分子抑制剂。

Cancer Metastasis Rev. 2020 Dec;39(4):1107-1126. doi: 10.1007/s10555-020-09911-9.

Targeting Endogenous K-RAS for Degradation through the Affinity-Directed Protein Missile System.通过亲和导向蛋白导弹系统靶向降解内源性K-RAS

Cell Chem Biol. 2020 Sep 17;27(9):1151-1163.e6. doi: 10.1016/j.chembiol.2020.06.012. Epub 2020 Jul 14.

Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers.利用 RAS 核苷酸循环作为靶向 RAS 驱动癌症的药物研发策略。

Int J Mol Sci. 2019 Dec 24;21(1):141. doi: 10.3390/ijms21010141.

From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers.从基础研究到KRAS驱动型癌症治疗策略的新成果

Cancer Biol Med. 2019 Aug;16(3):435-461. doi: 10.20892/j.issn.2095-3941.2018.0530.

Discovery and Structure-Based Optimization of Benzimidazole-Derived Activators of SOS1-Mediated Nucleotide Exchange on RAS.发现并基于结构优化苯并咪唑衍生物，激活 SOS1 介导的 RAS 核苷酸交换。

J Med Chem. 2018 Oct 11;61(19):8875-8894. doi: 10.1021/acs.jmedchem.8b01108. Epub 2018 Sep 28.

Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment.利用细胞内抗体片段筛选 RAS-效应蛋白相互作用的小分子抑制剂。

Nat Commun. 2018 Aug 9;9(1):3169. doi: 10.1038/s41467-018-05707-2.

BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions.基于 BRET 的 RAS 生物传感器显示，一种新型小分子是 RAS 效应蛋白-蛋白相互作用的抑制剂。

Elife. 2018 Jul 10;7:e37122. doi: 10.7554/eLife.37122.

Inhibition of the Ras/Raf interaction and repression of renal cancer xenografts by an enantiomeric iridium(iii) metal-based compound.一种对映体铱（III）金属基化合物对Ras/Raf相互作用的抑制及对肾癌异种移植瘤的抑制作用

Chem Sci. 2017 Jul 1;8(7):4756-4763. doi: 10.1039/c7sc00311k. Epub 2017 May 16.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Sulindac-derived Ras pathway inhibitors target the Ras-Raf interaction and downstream effectors in the Ras pathway.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献